Kelun-Biotech

Sichuan Kelun-Biotech Biopharmaceutical Co.,LTD (6990.HK) (hereinafter referred to as "KELUN-BIOTECH" or "the Company") is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs. Since its establishment in 2016, it has been committed to addressing medical needs in China and globally. With integrated drug development capabilities and a comprehensive management mechanism covering all key business functions, KELUN-BIOTECH is dedicated to internally developing differentiated therapies to enhance existing healthcare standards. As one of the pioneers and leading developers of Antibody-Drug Conjugates (ADCs), KELUN-BIOTECH has accumulated over a decade of experience in ADC development and is among the first biopharmaceutical companies in China, as well as globally, to establish an integrated ADC R&D platform, OptiDC. The company adopts a systematic, indication-oriented approach to address prevalent or difficult-to-treat cancers worldwide, as well as other diseases and conditions with large patient populations and unmet medical needs. Over the years, the company has built integrated capabilities encompassing all major drug development functions, including R&D, manufacturing, quality control, and commercialization, enabling the strategic and rapid advancement of a pipeline of 33 differentiated and clinically valuable assets, 14 of which are in clinical stages. Supported by three proprietary technology platforms, KELUN-BIOTECH possesses expertise in ADCs, large molecules (monoclonal antibodies (mAbs) and bispecific antibodies (bsAbs)), and small molecule drugs, validated by numerous clinical-stage candidates. The company has constructed a robust pipeline with diversity in drug modalities, mechanisms, and therapeutic coverage, capable of delivering synergistic effects. The controlling shareholder, Kelun Pharmaceuticals, with decades of experience, industry relationships, and an extensive network, has created favorable conditions for KELUN-BIOTECH to expand its commercial infrastructure and market channels. Meanwhile, the clinical value of KELUN-BIOTECH’s pipeline and its drug development capabilities have been recognized by global strategic partners. To date, the company has signed nine out-licensing agreements, including three license and collaboration agreements with Merck Sharp & Dohme LLC (together with its affiliates, "Merck") for the development of ADC assets for cancer treatment, with upfront and milestone payments exceeding $10 billion. These strategic collaborations not only demonstrate the company's R&D and business development capabilities but also serve as key drivers for continuous innovation, building global influence, and achieving long-term growth. Looking ahead, KELUN-BIOTECH will strive to advance the commercialization of its pipeline and enhance its integrated drug development capabilities, continue to lead the R&D and clinical activities of its candidate drugs, and focus on optimizing its R&D platform and developing new technologies to support innovative drug development. KELUN-BIOTECH will also continue to expand its cGMP manufacturing and quality control facilities and strengthen its internal commercialization functions to support the future launch of pipeline assets and achieve its goal of becoming a world-leading biopharmaceutical company.